3 recruiting, 1 withdrawn. 4 Phase 2, 2 Phase 1.
By phase and status
Follow Gastroesophageal Junction: new trials by email Literature Review of Gastroesophageal Junction trials Research Report on Gastroesophageal Junction
Trials (filtered) newest first · largest first
All 4 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Denikitug, Nivolumab, Ramucirumab - HER2-negative, Gastroesophageal Junction | Phase 2 | Recruiting | 120 | 2026-08-07 | 2026-09-21 |
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | 160 | 2024-09-20 | 2026-10-07 |
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | 210 | 2024-08-07 | 2026-09-03 |
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Relatlimab + Nivolumab, Nivolumab, Paclitaxel - Gastric Cancer, Cancer of the Stomach | Phase 2 | Withdrawn | | 2019-10-31 | 2020-05-19 |
Narrower conditions
Esophageal Neoplasms (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Adenocarcinoma Of Esophagus (1) · Stomach Neoplasms (1)
Broader conditions
Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Esophageal Diseases (2) · Head and Neck Neoplasms (2) · Stomach Diseases (1)
Interventions
Paclitaxel (3) · Ramucirumab (3) · Nivolumab (2) · patritumab deruxtecan (2) · Capecitabine (1) · Fluorouracil (1) · Leucovorin (1) · Levoleucovorin (1) · Oxaliplatin (1) · pembrolizumab (1) · relatlimab (1)
Sponsors
Merck Sharp & Dohme LLC (2) · Bristol-Myers Squibb (1) · Gilead Sciences (1)
Countries
United States (4) · Brazil (3) · Chile (3) · France (3) · Germany (3) · Italy (3) · South Korea (3) · Australia (2) · China (2) · Norway (2) · Spain (2) · Switzerland (2) · Taiwan (2) · Argentina (1) · Canada (1)
NIH funding
2023 (2), 2018 (1), 2025 (1)